Lipigon Pharmaceuticals AB
Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which… Read more
Lipigon Pharmaceuticals AB (LPGO) - Net Assets
Latest net assets as of September 2025: Skr15.09 Million SEK
Based on the latest financial reports, Lipigon Pharmaceuticals AB (LPGO) has net assets worth Skr15.09 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr18.08 Million) and total liabilities (Skr2.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr15.09 Million |
| % of Total Assets | 83.46% |
| Annual Growth Rate | -51.04% |
| 5-Year Change | -40.22% |
| 10-Year Change | N/A |
| Growth Volatility | 296.61 |
Lipigon Pharmaceuticals AB - Net Assets Trend (2017–2024)
This chart illustrates how Lipigon Pharmaceuticals AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lipigon Pharmaceuticals AB (2017–2024)
The table below shows the annual net assets of Lipigon Pharmaceuticals AB from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr7.76 Million | -72.71% |
| 2023-12-31 | Skr28.44 Million | +634.80% |
| 2022-12-31 | Skr3.87 Million | -83.14% |
| 2021-12-31 | Skr22.96 Million | +76.86% |
| 2020-12-31 | Skr12.98 Million | +498.57% |
| 2019-12-31 | Skr2.17 Million | +357.60% |
| 2018-12-31 | Skr-842.00K | -100.07% |
| 2017-12-31 | Skr1.15 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lipigon Pharmaceuticals AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 518538000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr587.00K | 7.56% |
| Other Comprehensive Income | Skr-999.00 | -0.01% |
| Other Components | Skr131.59 Million | 1695.72% |
| Total Equity | Skr7.76 Million | 100.00% |
Lipigon Pharmaceuticals AB Competitors by Market Cap
The table below lists competitors of Lipigon Pharmaceuticals AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TERADATA
BE:3T4
|
$248.49K |
|
Danske Invest Fjernosten
CO:DKIFJIX
|
$248.51K |
|
UCB-P-I
NASDAQ:UCB-P-I
|
$248.53K |
|
GAS NATURAL SDG
BE:GAN
|
$248.63K |
|
ANGLO AMERICAN (NGLB.SG)
STU:NGLB
|
$248.42K |
|
Jahwa Electronics Co. Ltd.
KQ:033240
|
$248.39K |
|
26U
F:26U
|
$248.33K |
|
Ellen AB (publ)
ST:ELN
|
$248.28K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lipigon Pharmaceuticals AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 28,445,000 to 7,760,000, a change of -20,685,000 (-72.7%).
- Net loss of 25,264,000 reduced equity.
- New share issuances of 4,841,000 increased equity.
- Other comprehensive income decreased equity by 1,999.
- Other factors decreased equity by 260,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-25.26 Million | -325.57% |
| Share Issuances | Skr4.84 Million | +62.38% |
| Other Comprehensive Income | Skr-2.00K | -0.03% |
| Other Changes | Skr-260.00K | -3.35% |
| Total Change | Skr- | -72.72% |
Book Value vs Market Value Analysis
This analysis compares Lipigon Pharmaceuticals AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.11x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.11x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | Skr91.87 | Skr0.01 | x |
| 2018-12-31 | Skr-0.07 | Skr0.01 | x |
| 2019-12-31 | Skr0.17 | Skr0.01 | x |
| 2020-12-31 | Skr0.98 | Skr0.01 | x |
| 2021-12-31 | Skr1.87 | Skr0.01 | x |
| 2022-12-31 | Skr0.22 | Skr0.01 | x |
| 2023-12-31 | Skr0.44 | Skr0.01 | x |
| 2024-12-31 | Skr0.06 | Skr0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lipigon Pharmaceuticals AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -325.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -245.59%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 1.91x
- Recent ROE (-325.57%) is below the historical average (-259.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -263.35% | 0.00% | 0.00x | 1.54x | Skr-3.15 Billion |
| 2018 | 0.00% | -125600.00% | 0.01x | 0.00x | Skr-3.68 Million |
| 2019 | -227.48% | -283.08% | 0.54x | 1.48x | Skr-5.15 Million |
| 2020 | -62.14% | -188.59% | 0.28x | 1.17x | Skr-9.37 Million |
| 2021 | -179.07% | -1293.02% | 0.11x | 1.28x | Skr-43.41 Million |
| 2022 | -973.08% | -9658.46% | 0.04x | 2.79x | Skr-38.06 Million |
| 2023 | -42.64% | -73.92% | 0.49x | 1.18x | Skr-14.97 Million |
| 2024 | -325.57% | -245.59% | 0.69x | 1.91x | Skr-26.04 Million |
Industry Comparison
This section compares Lipigon Pharmaceuticals AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lipigon Pharmaceuticals AB (LPGO) | Skr15.09 Million | -263.35% | 0.20x | $248.46K |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |